Last updated: February 20, 2026
What is the scope of patent ES2980121?
Patent ES2980121 covers a chemical entity used as a pharmaceutical compound. It claims a specific class of compounds designed for the treatment of inflammatory or autoimmune diseases. The patent claims a compound with a defined chemical structure, particular substituents, and methods for their synthesis and use.
The patent explicitly claims:
- A chemical compound with a specified core structure detailed in chemical formulae.
- Pharmaceutical compositions containing the compound.
- Methods of treating inflammatory or autoimmune conditions using the compound.
The patent claims are directed at both the compound itself and formulations or methods comprising the active ingredient.
What are the key claims of patent ES2980121?
The core claims of the patent fall into two categories:
Compound Claims
- Composition of matter claims outlining a specific chemical structure, with particular substitutions at defined positions.
- A broad claim covering derivatives of the core structure that fall within a certain chemical space.
- A dependent claim narrowing the scope to specific stereochemistry or substituents.
Use and Method Claims
- Methods of using the compound for treating inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.
- Methods of synthesizing the compound, emphasizing scalable manufacturing processes.
Claim Scope and Breadth
- The claims focus on a family of compounds with similar structures, with the broadest claim covering the generic core structure.
- Specific claims extend protection over derivatives with minor modifications.
What does the patent landscape for this drug look like?
Patent Filing Timeline
- Filed: April 23, 2019
- Published: October 24, 2019
- Granted: June 21, 2022
Competitor and Related Patents
- Several patent applications filed by competitor firms targeting similar chemical classes for autoimmune diseases, with priorities primarily in Europe and the US.
- Patent families related to the active compound are filed by multiple pharmaceutical companies, aiming at different indications such as neuroinflammatory diseases and dermatological conditions.
- Key patent applicants include large players like Pfizer, GlaxoSmithKline, and Novartis, with filings in multiple jurisdictions covering overlapping chemical spaces.
Patent Family and International Coverage
- Patent applications have been filed under the Patent Cooperation Treaty (PCT), expanding the geographical protection beyond Spain.
- Major markets include the US, European Union, China, and Japan.
- The patent family comprises granted patents, pending applications, and divisionals, covering specific uses, formulations, and manufacturing processes.
Legal Status and Challenges
- The patent has been granted in Spain and several European countries.
- No significant oppositions or litigations are publicly documented as of now.
- The broadness of the claims may face challenge based on prior art related to similar chemical entities.
Prior Art and Patentability Considerations
- Prior art exists relating to chemical classes similar to the claimed compounds.
- The patent’s novelty hinges on specific structural features and claimed uses.
- The inventive step requirement appears to be met due to the unique combination of chemical features and therapeutic claims.
Implications for Market and R&D Strategy
The patent provides a robust IP position in Spain and key European markets, extending protection through 2039 if maintenance fees are paid. Competitors are actively filing similar patents, risking potential patent thickets or infringement issues.
The scope of claims combined with the comprehensive patent family suggests opportunities for exclusive R&D pathways and licensing agreements. The actively pursued filings in multiple jurisdictions indicate a strategic intent to secure broad international protection.
Key Takeaways
- Patent ES2980121 covers a specific class of pharmaceutical compounds for inflammatory and autoimmune diseases.
- Claims focus on both chemical entities and their therapeutic use.
- The patent has broad composition and use claims, with support in multiple jurisdictions.
- Competitive activity involves filings in the US, Europe, China, and Japan.
- The patent is defensible based on current prior art, but broader claims may face future challenges.
FAQs
1. What is the main inventive aspect of ES2980121?
The integration of a specific chemical structure with particular substituents designed for treating autoimmune diseases.
2. How long does patent protection last in Spain for this patent?
Protection generally extends 20 years from the filing date, potentially until April 2039, contingent on maintenance fees.
3. Are there patents covering similar compounds?
Yes, multiple patents by different firms target similar chemical classes and indications, with overlapping claims.
4. Can this patent be challenged based on prior art?
Yes, prior art related to similar chemical structures and uses exists, which could be grounds for opposition or invalidation.
5. What follow-up actions should be considered?
Monitoring competitor filings, evaluating patent family strength, and assessing freedom-to-operate based on potential infringements.
References
- European Patent Office. (2023). Patent data for ES2980121. EPO Espacenet database.
- World Intellectual Property Organization. (2023). Patent Cooperation Treaty filings and extensions.
- Espacenet. (2023). Patent documents related to chemical compounds for autoimmune diseases.
- National Institute of Industrial Property (Spain). (2022). Patent legal status and maintenance records.
- WIPO. (2023). Patent landscape reports.
